Important information for our community: | |||
| COVID-19 Resource Center | Your Care During the Pandemic | ||
About Holy Name Medical Center201-833-3000
877-HOLY-NAME (465-9626)
201-833-3300
201-833-3187
201-833-7040
201-833-3352
For general questions or comments, email info@holyname.org
Learn more about these studies:
|
|
|
List of Clinical Studies |
|
| Multiple Sclerosis | |
| Study Name | Principal Investigator |
 |
|
|
101MS329– A randomized, controlled, open-label, rater-blinded, phase 3b study of the efficacy,
safety, and tolerability of 6-week extended interval dosing of Natalizumab (BG00002) in subjects
with relapsing-remitting multiple sclerosis switching from treatment with 4-week Natalizumab
standard interval dosing (SID) in relation to continued SID treatment. Read more. |
Mary Ann Picone, MD |
|
|
|
215MS202– A multicenter, randomized, double-blind, placebo-controlled study in subjects with
relapsing multiple sclerosis to evaluate the efficacy and safety of BIIB033 as an add-on therapy
to anti-inflammatory disease-modifying therapies. Read more. |
Mary Ann Picone, MD |
|
|
|
TG1101-RMS202– Phase III: UbLiTuximab in multiple sclerosis treatment effects. Read more. |
Mary Ann Picone, MD |
|
|
|
MSPT– Feasibility of the multiple sclerosis performance test for assessment of functional
performance measures in patients with multiple sclerosis. Read more. |
Mary Ann Picone, MD |
|
|
|
MEDDAY SPI2 – The purpose of this study is to demonstrate the superiority of MD1003 over
placebo in the disability of patients suffering from progressive multiple sclerosis and especially
those with gait impairment. Read more. |
Mary Ann Picone, MD |
|
|
|
MN30035– A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis
(RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying
Treatment (DMT). Read more. |
Mary Ann Picone, MD |
|
|
|
WA25046– A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis. Read more. |
Mary Ann Picone, MD |
|
|
